文献速递心血管US

二尖瓣反流严重程度与左心室重构对MitraClip植入术后结局的影响:MITRA-FR试验结果

Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After MitraClip Implantation: Results From the Mitra-FR Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2020-09-16

MITRA-FR试验事后分析按二尖瓣反流严重程度(ERO、RVOL、RF)、左心室重构(舒张/收缩末期内径和容积)及两者组合划分亚组,评估MitraClip介入与24个月全因死亡或心衰非计划住院复合终点的交互作用。结果显示,无论反流最重亚组(ERO≥30 mm²、RVOL≥45 ml或RF≥50%)、反流较轻亚组、左心室重构较轻亚组,还是两者组合(包括ERO/舒张末期容积比值≥0.15的「不成比例反流」亚组),介入均呈中性影响,未识别出可能获益的患者亚组。

要点

  • 按二尖瓣反流严重程度(ERO、RVOL、RF)划分的各亚组中,MitraClip介入对24个月复合终点均无获益。
  • 按左心室重构(舒张/收缩末期内径和容积)划分的较轻重构亚组中,介入同样呈中性影响。
  • 反流与重构参数组合后仍无获益,包括ERO/舒张末期容积比值≥0.15的「不成比例反流」亚组。

核心结论

  • 在MITRA-FR试验中,依据反流程度、左心室重构或两者组合定义的亚组(包括ERO/舒张末期容积比值≥0.15的「不成比例反流」亚组)均未显示MitraClip经导管修复可获益。

研究设计与样本

  • MITRA-FR试验(NCT01920698)的事后分析,评估介入与按超声参数划分的患者亚组之间的交互作用。
  • 亚组划分依据包括反流严重程度(ERO、RVOL、RF)、左心室重构(舒张末期和收缩末期内径及容积)以及这些参数的组合。

诊断标准与关键数值

  • 反流最重亚组定义为ERO≥30 mm²、RVOL≥45 ml或RF≥50%,介入对该亚组24个月全因死亡或心衰非计划住院复合终点呈中性影响。
  • 反流较轻亚组中介入同样呈中性影响。
  • 左心室重构较轻亚组(按舒张或收缩末期内径或容积定义)中介入同样呈中性影响。
  • 反流与重构参数组合后仍无获益,包括ERO/舒张末期容积比值≥0.15的亚组(该亚组ERO与左心室舒张末期容积与COAPT患者相似)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 本文为MITRA-FR试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to identify a subset of patients based on echocardiographic parameters who might have benefited from transcatheter correction using the MitraClip system in the MITRA-FR (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation) trial.

BACKGROUND: It has been suggested that differences in the degree of mitral regurgitation (MR) and left ventricular (LV) remodeling may explain the conflicting results between the MITRA-FR and the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trials.

METHODS: In a post hoc analysis, we evaluated the interaction between the intervention and subsets of patients defined based on MR severity (effective regurgitant orifice [ERO], regurgitant volume [RVOL] and regurgitant fraction [RF]), LV remodeling (end-diastolic and end-systolic diameters and volumes) and combination of these parameters with respect to the composite of death from any cause or unplanned hospitalization for heart failure at 24 months.

RESULTS: We observed a neutral impact of the intervention in subsets with the highest MR degree (ERO ≥30 mm2, RVOL ≥45 ml or RF ≥50%) as in patients with milder MR degree. The same was seen in subsets with the milder LV remodeling using either diastolic or systolic diameters or volumes. When parameters of MR severity and LV remodeling were combined, there was still no benefit of the intervention including in the subset of patients with an ERO/end-diastolic volume ratio ≥ 0.15 despite similar ERO and LV end-diastolic volume compared with COAPT patients.

CONCLUSIONS: In the MITRA-FR trial, we could not identify a subset of patients defined based on the degree of the regurgitation, LV remodeling or on their combination, including those deemed as having disproportionate MR, that might have benefited from transcatheter correction using the MitraClip system. (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation [MITRA-FR]; NCT01920698).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Messika-Zeitoun D, Iung B, Armoiry X, et al. Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After MitraClip Implantation: Results From the Mitra-FR Trial. JACC Cardiovasc Imaging. 2020. PMID: 32950444. doi:10.1016/j.jcmg.2020.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。